Inozyme Pharma(INZY)
Search documents
Inozyme Pharma (INZY) Investor Presentation - Slideshow
2022-12-09 14:34
| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ı | | | | | | | Our Mission | | | | | | | Fulfill an unmet medical need with therapeutic breakthroughs in rare diseases of pathologic mineralization and intimal proliferation | | | | | | December 2022 Legal Di ...
Inozyme Pharma(INZY) - 2022 Q3 - Quarterly Report
2022-11-10 14:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) ...
Inozyme Pharma(INZY) - 2022 Q2 - Quarterly Report
2022-08-15 11:52
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) Dela ...
Inozyme Pharma (INZY) Investor Presentation - Slideshow
2022-05-24 19:02
| --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ı | | | | | | Our Mission | | | | | | Fulfill an unmet medical need with therapeutic breakthroughs in diseases of abnormal mineralization | | | | | May 2022 Legal Disclaimer This presentation and any statements made orally during this presentation also contain estimat ...
Inozyme Pharma(INZY) - 2022 Q1 - Quarterly Report
2022-05-10 11:44
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) (St ...
Inozyme Pharma (INZY) Investor Presentation - Slideshow
2022-04-13 18:06
| --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ı | | | | | | Our Mission | | | | | | Fulfill an unmet medical need with therapeutic breakthroughs in diseases of abnormal mineralization | | | | | April 2022 Legal Disclaimer This presentation and any statements made orally during this presentation also contain estimates and oth ...
Inozyme Pharma(INZY) - 2021 Q4 - Annual Report
2022-03-15 21:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) (State o ...
Inozyme Pharma(INZY) - 2021 Q3 - Quarterly Report
2021-11-09 21:40
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) ...
Inozyme Pharma(INZY) - 2021 Q2 - Quarterly Report
2021-08-11 10:20
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) Dela ...
Inozyme Pharma(INZY) - 2021 Q1 - Quarterly Report
2021-05-12 10:19
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) Del ...